slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 74,521-74,550
Pages 3,679
Rows per page 30
Component
74,521-74,550 of 110,355
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
17
The slide uses a process flow diagram to illustrate a clinical success story.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
18
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
26
The scatter plot highlights a specific cluster of 'active learning' selections that deviate from the standard Pareto frontier.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
33
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
39
Venn diagram shows overlap of gene modulation; line charts show dose-response for POLR2A and HNRNPDL.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
46
The slide uses a human anatomy diagram to map specific disease indications to their respective patient counts.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
47
Includes a biological pathway diagram showing LSD1 interactions with various complexes and substrates.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
48
Includes a biological pathway diagram and supporting bullet points on therapeutic mechanism and safety profile.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
54
The chart illustrates a Pareto front in drug discovery, highlighting that the 'best' molecules (on the front) are not always the most information-rich for further development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
56
Includes box plots for overall differentiation and line plots for patient-specific heterogeneity categorized by differentiation level.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
57
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across 6 different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
58
The slide shows two charts: a line chart for tumour volume over time and a dot plot for plasma pro-GRP concentration. Statistical significance markers are present.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
60
The heatmap displays AUC (Response) values across 16 patient samples for three different treatments.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
71
The slide demonstrates efficacy and synergy in vivo for a drug candidate ('565) in DLBCL models.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
72
The slide uses two dose-response curves to demonstrate selectivity.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
73
The table uses a heatmap-style color coding (red/green) to indicate risk levels for UGT1A1 inhibition parameters.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
05
The chart uses a horizontal bar format to represent development stages.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
08
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
10
The slide uses a process flow to show the mechanism of action for a drug candidate.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
11
The slide contrasts irreversible inhibition (depletion) with reversible inhibition (recovery).Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
12
The slide includes two charts: a line chart showing tumour volume over time and a dot plot showing plasma pro-GRP concentration reduction.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
13
The slide uses box plots for aggregate data and line charts for individual patient sample responses, categorized by differentiation level.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Evidence1 hit
14
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across different drug combinations.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Evidence1 hit
17
Data shows significant synergistic effects in both models, with OCI-Ly10 showing regression and TMD8 showing synergy despite ibrutinib monotherapy inactivity.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
19
The table uses a heatmap-style color coding (red for high risk, green for low risk) to visualize safety metrics.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
22
Includes footnote regarding fixed term bank deposits and currency basis.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Key Messages1 hit
05
The slide uses a high-contrast background image of the vehicle to emphasize the 'TechLuxury' brand positioning.Faraday Future | Results Presentation Deck | 38 slides · Faraday Future
Conference presentation Investor relations Beat · Humble Origins1 hit